Connect with us

Hi, what are you looking for?

Trade Strategy LabTrade Strategy Lab

Investing

Tartisan Nickel: Working Towards a Feasibility Study and Production Decision at the Kenbridge Nickel Deposit

Tartisan Nickel (CSE:TN,OTCQX:TTSRF,FSE: 8TA) is a Canadian exploration and development company focused on advancing high-quality critical mineral assets in Ontario. Its flagship asset, the Kenbridge nickel project in Northwestern Ontario, is an advanced-stage nickel sulphide deposit containing nickel, copper and cobalt.

Management’s strategy for Kenbridge is clear and execution-driven: expand and upgrade the resource through drilling, extend potential mine life, and continue systematically de-risking the project.

Tartisan Nickel has been engaging with Treaty # 3 First Nations since May 2007.

At the same time, Tartisan holds the Sill Lake silver project, a past-producing silver-lead property near Sault Ste. Marie, Ontario. Supported by strong fundamentals for nickel, copper and silver, management positions Tartisan as a multi-asset story—providing investors with exposure to several value drivers within a single platform.

Company Highlights

  • Clear focus on drilling-driven value creation, with active programs designed to upgrade inferred resources, expand the deposit at depth, and extend mine life into the mid-teens
  • Low-capex development profile relative to many peer nickel projects, supported by a historic shaft, road access, and established infrastructure
  • Sill Lake Silver Project provides additional, underappreciated value, offering exposure to silver through a brownfields, past-producing asset with a defined historic resource
  • Experienced leadership team with deep capital markets and mine development experience, focused on disciplined capital allocation and unlocking value from opportunity-acquired assets

This Tartisan Nickel profile is part of a paid investor education campaign.*

Click here to connect with Tartisan Nickel (CSE:TN,OTCQX:TTSRF,FSE: 8TA) to receive an Investor Presentation

This post appeared first on investingnews.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Investing

Radiopharm Theranostics (ASX:RAD, ‘Radiopharm’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need,...

Stock

Is the market’s next surge already underway? Find out with Tom Bowley’s breakdown of where the money is flowing now and how you can get...

Stock

Markets don’t usually hit record highs, risk falling into bearish territory, and spring back to new highs within six months. But that’s what happened...

Stock

Over the past five sessions, the Indian equity markets headed nowhere and continued consolidating in a defined range. In the previous weekly note, it...